IL13 and asthma: In the Phase IIa trial (NCT00873860), a subgroup of moderate to severe uncontrolled asthmatics who had elevated sputum IL-13 at baseline showed trends toward meaningful enhancements in Asthma Control Questionnaire (ACQ-6) scores and FEV1 when compared with placebo [185] (Figure 2).